Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 20 | 2021 | 666 | 4.730 |
Why?
|
| Mastectomy | 11 | 2019 | 59 | 2.780 |
Why?
|
| Breast Neoplasms, Male | 3 | 2018 | 11 | 1.550 |
Why?
|
| Mastectomy, Segmental | 7 | 2021 | 23 | 1.380 |
Why?
|
| Genes, BRCA2 | 4 | 2018 | 7 | 1.320 |
Why?
|
| Genes, BRCA1 | 4 | 2018 | 9 | 1.310 |
Why?
|
| Mutation | 3 | 2018 | 466 | 1.290 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2018 | 17 | 1.250 |
Why?
|
| Carcinoma, Papillary | 2 | 2016 | 13 | 1.050 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 12 | 0.950 |
Why?
|
| Genetic Testing | 3 | 2013 | 90 | 0.870 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 546 | 0.690 |
Why?
|
| Mammaplasty | 3 | 2018 | 27 | 0.670 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 58 | 0.650 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 436 | 0.640 |
Why?
|
| Biopsy | 2 | 2017 | 241 | 0.630 |
Why?
|
| Aged | 17 | 2021 | 9492 | 0.620 |
Why?
|
| Female | 21 | 2021 | 18173 | 0.620 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2014 | 69 | 0.610 |
Why?
|
| Paget's Disease, Mammary | 1 | 2017 | 3 | 0.610 |
Why?
|
| Humans | 27 | 2021 | 29123 | 0.580 |
Why?
|
| Middle Aged | 17 | 2021 | 10834 | 0.570 |
Why?
|
| Decision Making | 1 | 2018 | 180 | 0.570 |
Why?
|
| Retrospective Studies | 11 | 2019 | 3112 | 0.540 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2011 | 28 | 0.520 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 2109 | 0.500 |
Why?
|
| Breast Cyst | 1 | 2014 | 2 | 0.490 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 3719 | 0.450 |
Why?
|
| Taxoids | 1 | 2013 | 47 | 0.450 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 87 | 0.440 |
Why?
|
| African Americans | 3 | 2016 | 1373 | 0.440 |
Why?
|
| Anthracyclines | 1 | 2013 | 51 | 0.440 |
Why?
|
| Secretin | 2 | 2002 | 2 | 0.430 |
Why?
|
| Bicarbonates | 2 | 2002 | 11 | 0.430 |
Why?
|
| Obesity | 2 | 2018 | 1063 | 0.430 |
Why?
|
| European Continental Ancestry Group | 2 | 2016 | 1131 | 0.430 |
Why?
|
| Tissue Expansion Devices | 1 | 2011 | 10 | 0.420 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2011 | 2 | 0.410 |
Why?
|
| Treatment Outcome | 7 | 2021 | 3101 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2013 | 337 | 0.410 |
Why?
|
| Cytological Techniques | 1 | 2011 | 19 | 0.410 |
Why?
|
| Pancreas | 2 | 2002 | 79 | 0.410 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 20 | 0.400 |
Why?
|
| Secondary Prevention | 1 | 2011 | 59 | 0.400 |
Why?
|
| Surgical Flaps | 1 | 2011 | 69 | 0.400 |
Why?
|
| Adult | 11 | 2021 | 8426 | 0.390 |
Why?
|
| Lymphatic Metastasis | 4 | 2016 | 156 | 0.380 |
Why?
|
| Age Factors | 5 | 2017 | 1108 | 0.380 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 222 | 0.360 |
Why?
|
| Lymph Node Excision | 3 | 2019 | 89 | 0.320 |
Why?
|
| SEER Program | 2 | 2016 | 32 | 0.290 |
Why?
|
| Risk Assessment | 4 | 2018 | 1306 | 0.280 |
Why?
|
| Heterozygote | 2 | 2018 | 52 | 0.270 |
Why?
|
| Mammography | 2 | 2018 | 37 | 0.230 |
Why?
|
| Gastroplasty | 1 | 2002 | 11 | 0.220 |
Why?
|
| Gastric Bypass | 1 | 2002 | 28 | 0.220 |
Why?
|
| Survival Rate | 2 | 2016 | 795 | 0.220 |
Why?
|
| Captopril | 1 | 2002 | 8 | 0.210 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 281 | 0.210 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 134 | 0.200 |
Why?
|
| Hypoglycemic Agents | 1 | 2002 | 176 | 0.190 |
Why?
|
| Risk Factors | 3 | 2018 | 3537 | 0.190 |
Why?
|
| Insulin | 1 | 2002 | 346 | 0.180 |
Why?
|
| Liver Function Tests | 1 | 2019 | 19 | 0.170 |
Why?
|
| Blood Cell Count | 1 | 2019 | 26 | 0.170 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 43 | 0.170 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 67 | 0.170 |
Why?
|
| Breast | 1 | 2018 | 53 | 0.160 |
Why?
|
| Adolescent | 2 | 2018 | 3255 | 0.160 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 74 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2016 | 60 | 0.140 |
Why?
|
| Receptor, erbB-2 | 2 | 2014 | 45 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2014 | 89 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2018 | 332 | 0.140 |
Why?
|
| Body Mass Index | 2 | 2018 | 865 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2017 | 1688 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 525 | 0.140 |
Why?
|
| Chemoprevention | 1 | 2015 | 9 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2016 | 74 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 189 | 0.130 |
Why?
|
| Survivors | 1 | 2016 | 145 | 0.130 |
Why?
|
| Certification | 1 | 2015 | 24 | 0.130 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 45 | 0.130 |
Why?
|
| Comorbidity | 1 | 2016 | 540 | 0.130 |
Why?
|
| Male | 4 | 2018 | 17815 | 0.130 |
Why?
|
| Ultrasonography, Mammary | 1 | 2014 | 3 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2014 | 20 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 709 | 0.120 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 50 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 493 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 726 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2018 | 670 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 56 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 163 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 519 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2015 | 307 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 199 | 0.100 |
Why?
|
| Dogs | 2 | 2002 | 117 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 68 | 0.100 |
Why?
|
| Intraoperative Period | 1 | 2011 | 37 | 0.100 |
Why?
|
| Cytodiagnosis | 1 | 2011 | 16 | 0.100 |
Why?
|
| Young Adult | 2 | 2019 | 2402 | 0.100 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2010 | 2 | 0.100 |
Why?
|
| Time Factors | 1 | 2015 | 2001 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 532 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2010 | 92 | 0.090 |
Why?
|
| United States | 1 | 2018 | 3632 | 0.090 |
Why?
|
| North Carolina | 1 | 2011 | 1423 | 0.070 |
Why?
|
| Aromatase Inhibitors | 1 | 2005 | 7 | 0.070 |
Why?
|
| Tamoxifen | 1 | 2005 | 48 | 0.060 |
Why?
|
| Biliopancreatic Diversion | 1 | 2002 | 3 | 0.060 |
Why?
|
| Mass Screening | 1 | 2005 | 223 | 0.060 |
Why?
|
| Postmenopause | 1 | 2005 | 397 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2002 | 91 | 0.050 |
Why?
|
| Bethanechol | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cholinergic Agonists | 1 | 2002 | 3 | 0.050 |
Why?
|
| Parasympathomimetics | 1 | 2002 | 3 | 0.050 |
Why?
|
| Glucose Clamp Technique | 1 | 2002 | 12 | 0.050 |
Why?
|
| Pancreatic Juice | 1 | 2002 | 1 | 0.050 |
Why?
|
| Counseling | 1 | 2002 | 85 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 80 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2002 | 55 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 2021 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 836 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2002 | 279 | 0.050 |
Why?
|
| Animals | 2 | 2002 | 7300 | 0.050 |
Why?
|
| Weight Loss | 1 | 2002 | 413 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2002 | 466 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 23 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 787 | 0.040 |
Why?
|
| Health Surveys | 1 | 2016 | 191 | 0.040 |
Why?
|
| Registries | 2 | 2008 | 278 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 240 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 637 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 66 | 0.030 |
Why?
|
| General Surgery | 1 | 2015 | 81 | 0.030 |
Why?
|
| Quality of Life | 1 | 2016 | 816 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2010 | 48 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 159 | 0.020 |
Why?
|
| West Virginia | 1 | 2008 | 8 | 0.020 |
Why?
|
| Appalachian Region | 1 | 2008 | 16 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 45 | 0.020 |
Why?
|
| Rural Population | 1 | 2008 | 246 | 0.020 |
Why?
|
| Massachusetts | 1 | 2005 | 28 | 0.020 |
Why?
|
| Pedigree | 1 | 2005 | 133 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 198 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2005 | 440 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1119 | 0.010 |
Why?
|